First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties

[1]  F. Locatelli,et al.  New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology , 2019, Journal of Nephrology.

[2]  T. Akizawa,et al.  Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[3]  Jena Patel,et al.  Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis. , 2018, P & T : a peer-reviewed journal for formulary management.

[4]  T. Sakairi,et al.  Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. , 2018, Bioorganic & medicinal chemistry letters.

[5]  T. Akizawa,et al.  A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro , 2018, PloS one.

[6]  T. Nickolas,et al.  KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  K. Reinier,et al.  Serum Calcium and Risk of Sudden Cardiac Arrest in the General Population , 2017, Mayo Clinic proceedings.

[8]  D. Wheeler,et al.  KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) , 2017, Kidney international supplements.

[9]  G. Chertow,et al.  Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial , 2017, JAMA.

[10]  Benjamin Wu,et al.  Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing , 2016, Kidney international reports.

[11]  J. P. Perez Ruixo,et al.  Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium‐sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis , 2015, Journal of clinical pharmacology.

[12]  Zhen Wang,et al.  Reversible cardiac dysfunction associated with hypocalcemia: a systematic review and meta-analysis of individual patient data , 2014, Heart Failure Reviews.

[13]  S. Fukuhara,et al.  Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan , 2013, Kidney international supplements.

[14]  K. Iseki,et al.  Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[15]  John Cunningham,et al.  Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[16]  D. Coyne,et al.  Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients , 2010, Hemodialysis international. International Symposium on Home Hemodialysis.

[17]  Eiji Uchida,et al.  Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  B. Culleton,et al.  Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[20]  S. Rosansky,et al.  The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[21]  W. Goodman,et al.  Recent developments in the management of secondary hyperparathyroidism. , 2001, Kidney international.

[22]  F. M. van der Sande,et al.  Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  P. Squires,et al.  Expression of the calcium-sensing receptor on human antral gastrin cells in culture. , 1997, The Journal of clinical investigation.

[24]  M. Kleerekoper,et al.  Blood pressure response to changes in serum ionized calcium during hemodialysis. , 1986, Annals of internal medicine.